Go to content
UR Home

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

URN to cite this document:
urn:nbn:de:bvb:355-epub-375200
DOI to cite this document:
10.5283/epub.37520
Launay, Odile ; Duval, Xavier ; Fitoussi, Serge ; Jilg, Wolfgang ; Kerdpanich, Angkool ; Montellano, May ; Schwarz, Tino F. ; Watanveerade, Veerachai ; Wenzel, Jürgen J. ; Zalcman, Gerard ; Bambure, Vinod ; Li, Ping ; Caplanusi, Adrian ; Madan, Anuradha ; Gillard, Paul ; Vaughn, David W.
[img]
Preview
PDF - Published Version
(1MB)
Date of publication of this fulltext: 13 Aug 2018 13:04



Abstract

Background Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan). Methods In two studies, 334 adults 18-60 years ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons